花旗發表報告，料微創醫療(00853.HK)上半年收入勝市場預期，主因本地手術進行量復甦帶來的強勁銷售增長。展開30日正面催化劑觀察，予「買入」評級，目標價30元。
《大行報告》花旗對微創醫療(00853.HK)展開30日正面催化劑觀察 料中期收入勝預期
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.